Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome.
Tan LY, Mintoff C, Johan MZ, Ebert BW, Fedele C, Zhang YF, Szeto P, Sheppard KE, McArthur GA, Foster-Smith E, Ruszkiewicz A, Brown MP, Bonder CS, Shackleton M, Ebert LM.
Tan LY, et al. Among authors: ruszkiewicz a.
Oncotarget. 2016 Jul 19;7(29):46492-46508. doi: 10.18632/oncotarget.10216.
Oncotarget. 2016.
PMID: 27340778
Free PMC article.